Roelof Botha, a director at Natera, Inc. (NASDAQ:NTRA), recently sold a significant portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Botha sold a total of 87,473 shares of Natera's common stock on December 2, 2024. The sale comes as the $23 billion market cap company trades near its 52-week high of $171.95, having delivered an impressive 185% return over the past year. The shares were sold in multiple transactions at prices ranging from $166.88 to $170.54, resulting in a total sale value of approximately $14.79 million.
Following these transactions, Botha's indirect ownership, held through estate planning vehicles, decreased, leaving him with 1,224,787 shares of Natera common stock. This move is part of Botha's ongoing management of his investment portfolio.
In other recent news, Natera Inc (NASDAQ:NTRA). faced a setback in a false advertising lawsuit with Guardant Health (NASDAQ:GH), with the jury ruling in Guardant's favor. However, Natera has expressed disagreement with the verdict and plans to request the court to overturn the decision. Despite this legal challenge, Natera reported record Q3 revenue of $439.8 million, a 64% increase year-over-year, and conducted 137,000 oncology tests, marking a 54% increase from the previous year.
These robust financial results led to an upward revision of the company's full-year revenue guidance to between $1.61 billion and $1.64 billion. Analysts from TD Cowen, Baird, and Jefferies have maintained favorable ratings on Natera's stock and raised their price targets, reflecting confidence in the company's operational success and continued growth.
Despite challenges with private payers and potential holiday-related disruptions in Q4, Natera sees significant growth opportunities ahead with over 100 trials underway. The company's Signatera test, a major revenue-contributing product, showed promising results in predicting overall survival and chemotherapy benefits in colorectal cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.